China IVF Industry Trends 2025: Technology Advances and Policy Adjustment Observations

China IVF Industry Trends: Real Changes in 2025 and Practitioner Observations

The current assisted reproductive industry in China is undergoing three core changes: The pace of technology approval is accelerating, costs at public hospitals are decreasing, and fertility preservation is moving from a "subculture" to the mainstream. The following content is compiled based on frontline feedback from 14 reproductive centers nationwide and public policies, and does not contain any institutional promotional information.

The Five Most Core Industry Dynamics in 2025

• Clinical application of third-generation IVF (PGT) expanded to more centers: As of Q1 2025, the number of institutions with PGT qualifications nationwide has increased from 68 to 92, with some provincial-level major hospitals receiving approval for the first time. The range of indications has expanded from monogenic diseases to chromosomal structural abnormalities and recurrent miscarriage.
• Public hospital IVF package prices reduced by 10%~20%: Beijing, Shanghai, and Guangdong have introduced price adjustment plans for assisted reproductive medical services. Some examination items (e.g., sex hormone six tests, AMH, ultrasound follicle monitoring) are now covered by personal medical insurance accounts.
• More cities open egg freezing for non-medical reasons: Following Beijing and Shanghai, Chengdu, Hangzhou, and Wuhan now allow unmarried women aged 25-40 to freeze eggs under the name of "fertility preservation," requiring medical evaluation and ethical filing.
• Extended waiting period for egg donation, official registration system in trial operation: The National Health Commission requires all centers authorized to perform egg donation to connect to a unified information platform, expected to reduce the current average waiting time of 2-4 years to 1-1.5 years. However, initial data entry delays have led some centers to suspend new registrations.
• AI-assisted embryo evaluation enters clinical validation phase: At least 8 top reproductive centers have deployed AI grading systems based on time-lapse imaging in embryo culture rooms to assist in determining blastocyst transfer priority, though they have not yet replaced manual scoring.

Driving Factors Behind These Changes

The adjustments in China's IVF industry trends are mainly due to three reasons:

• Population policy and fertility support orientation: After the draft revision of the "Regulations on the Management of Assisted Reproductive Technology" was solicited for comments in 2024, the pace of industry approvals has significantly accelerated. Local health commissions have listed reducing treatment costs for infertile couples as a livelihood project indicator.
• Technological maturity and clinical demand driving access: Embryo biopsy techniques for third-generation IVF (PGT) have been standardized, and laboratory personnel training systems are gradually improving. Meanwhile, the proportion of first IVF cycles for advanced maternal age (≥35 years) has risen from 42% in 2020 to 61% in 2025, with this group showing a strong willingness for embryo screening.
• Commercial pressure forcing public hospitals to reduce fees: Private reproductive chain institutions (e.g., Jinxin, Aiwei Aifu, etc.) are capturing market share in second-tier cities, forcing public hospitals to lower costs through centralized procurement of consumables and process optimization. In the first half of 2025, the total cost of a routine IVF cycle (excluding medication) at some tertiary hospitals dropped to 28,000~35,000 RMB.

Consensus Among Reproductive Center Doctors on Industry Trends

In non-public discussions at the 2025 Chinese Society of Reproductive Medicine Annual Conference, several chief physicians expressed the following views:

• Regarding PGT popularization: Caution should be exercised against expanding indications, and embryo screening should be recommended cautiously for couples without clear genetic indications. Currently, about 30% of PGT applications do not meet official guidelines, but patient expectations are too high, requiring doctors to bear the cost of education.
• Regarding egg freezing: The survival rate of eggs frozen for non-medical reasons (85%~90%) is significantly lower than for medical reasons (90%~95%), mainly because the former's egg quality is more affected by age delay. Doctors recommend the target group to be 30-35 years old, rather than 25.
• Regarding AI embryo evaluation: Currently, AI has high accuracy in "predicting blastocyst morphology," but has not yet reached the necessary threshold for clinical decision-making in "predicting genetic normality" and "predicting live birth rate." At least 2-3 more years of real-world data are needed.

Specific Impacts of Industry Dynamics on Different Age Groups

Differences in Industry Landscape Between China and Overseas IVF

Although domestic industry dynamics are changing rapidly, there are still significant differences compared to the US/Japan/Thailand:

• Technology accessibility: In China, PGT requires government-approved indications, while the US allows all patients to choose freely; Japan uses blastocyst culture completion rate as a center quality indicator, while China emphasizes clinical pregnancy rate more.
• Cost structure: A standard IVF cycle (including medication) in a Chinese public hospital costs about 30,000~50,000 RMB (after 2025 price reductions), compared to an average of $20,000~$30,000 in the US and $10,000~$20,000 in Thailand. Medical insurance coverage in China is very low (only partial reimbursement for examination fees), but absolute out-of-pocket costs are lower than overseas.
• Medication habits: China still primarily uses domestic ovulation induction drugs (urinary FSH), with imported Gonal-f accounting for about 35%; overseas generally uses recombinant FSH and is more flexible in using GnRH antagonists.
• Embryo culture duration: About 70% of domestic centers perform day 5 (D5) blastocyst transfer, 20% continue culture to D6; overseas, such as the US, over 95% of centers only transfer D5/6 blastocysts, discarding D3 embryos.

Strategic Differences Among Different Types of Reproductive Centers

Five Details Often Overlooked by Patients in Industry Dynamics

• PGT qualification ≠ full popularization: Some newly approved PGT hospitals may initially only perform PGT-A (chromosomal aneuploidy screening) and not PGT-M (monogenic diseases); need to confirm in advance.
• All required examinations before egg freezing: In addition to routine AMH, FSH, and ultrasound, pelvic MRI (to rule out fibroids/adenomyosis), genetic counseling (to rule out genetic disease carrier status), and psychiatric evaluation (required in some cities) are also required.
• Changes in IVF filing materials: From 2025, some provinces require a "fertility registration certificate" (electronic version) instead of the previous "birth permit," but many centers still prefer paper, so it is necessary to obtain it from the community service station in advance.
• Limitations of medical insurance coverage: Even if examination fees can be covered by medical insurance, ovulation induction drugs (e.g., Gonal-f), transfer surgery fees, and embryo freezing fees are not in the reimbursement catalog. The actual out-of-pocket ratio may actually decrease due to examination fee reductions.
• "False window" in egg donation waiting period: After the unified registration system goes online, the official average waiting time is 18 months, but the actual wait for an egg source to appear and match successfully may exceed 3 years in some centers due to blood type, antibodies, and other reasons.

High-Frequency Pitfalls When Trying New Policies/Technologies

1. The "prisoner's dilemma" of not considering thawing after egg freezing: After policies allowed egg freezing, many women repeatedly freeze 4-5 times, but upon actual thawing, the survival rate is only 80%~90%, and the probability of each egg leading to a successful live birth is about 5%~8%. Do not undergo repeated stimulation just to "stockpile eggs."
2. Overinterpretation of AI embryo grading: Some private hospitals use AI scores of "A+" as a point for fee upgrades, but the correlation coefficient between AI scores and final live birth is r=0.3~0.4, which cannot be used as a sole decision-making basis. Real decisions still need to combine embryo morphology, PGT results, and maternal factors.
3. Failure to update examinations after egg donation registration: The official system requires registered patients to update infectious disease screenings (HIV, hepatitis B, syphilis) and blood type re-testing every six months, otherwise they are automatically removed from the queue. Many people are thus kicked off the waiting list.

Updated Points in the Standard IVF Process from Industry Dynamics

• Initial visit: Basic examinations (sex hormone six tests, AMH, ultrasound) can now be done using medical insurance.
• Protocol formulation: Advanced-age patients are more inclined to use PPOS or mild stimulation; public hospitals can use domestic ovulation induction drugs (Lishenbao) to reduce costs.
• Egg retrieval: Most centers use painless anesthesia (intravenous general anesthesia); some hospitals have begun implementing "follicle aspiration" as an auxiliary treatment.
• Embryo evaluation: AI-assisted grading can be chosen (but at an additional cost); before PGT-A testing, an informed consent form must be signed, clearly stating that a normal embryo cannot be guaranteed.
• Transfer: The proportion of frozen embryo cycles has exceeded fresh embryos (about 65%) because endometrial preparation is more controllable and genetic screening can be completed in advance.
• Luteal support: Oral dydrogesterone + Crinone gel remain mainstream; some hospitals recommend adding a GnRH agonist as a "luteal support enhancement protocol."

Suggested Timeline Planning for IVF Cycles in 2025

Practitioner Perspective: The Real Temperature of the Industry in 2025

As a medical editor working in a tertiary reproductive center in East China, I have observed the following phenomena:

• Significant increase in patient education time: Due to policy liberalization (egg freezing, PGT), initial consultation questions in the past six months have focused on "Can I do third-generation IVF?" and "Does egg freezing affect the ovaries?" Doctors spend a lot of time explaining indications rather than treatment plans. It is recommended that patients complete knowledge self-tests on official platforms in advance (such as the "Assisted Reproductive Science Q&A" published by the Health Commission).
• Accelerated turnover of medical teams: High salaries offered by private institutions have led to the departure of key personnel from some tertiary reproductive centers, causing short-term fluctuations in overall departmental success rates. One director privately revealed that the turnover rate in 2025 is about 12%. This can affect the choice of primary surgeon for new patients.
• Laboratory equipment upgrade race: The push for AI embryo evaluation is driven not by clinical need but by the KPIs of equipment manufacturers and hospital management. The utilization rate of AI systems in some center laboratories is less than 40% because embryologists do not trust machine judgments and insist on manual scoring.